TELA Bio (TELA) EBITDA (2018 - 2026)

TELA Bio's EBITDA history runs 9 years deep, the most recent figure standing at -$12.3 million for Q1 2026.

• In Q1 2026, EBITDA fell 9.02% year-over-year to -$12.3 million; the TTM figure through Mar 2026 stood at -$39.8 million (up 8.29% YoY), while the FY2025 annual figure was -$38.8 million, down 2.61% from the prior year.
• EBITDA was -$12.3 million for Q1 2026 at TELA Bio, down from -$9.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$5.7 million in Q1 2024 to a low of -$12.9 million in Q4 2023.
• Historically, EBITDA has averaged -$10.3 million across 5 years, with a median of -$10.2 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBITDA jumped 53.1% in 2024, then slumped 99.17% in 2025.
• A 5-year view of EBITDA shows it stood at -$9.4 million in 2022, then plunged by 37.03% to -$12.9 million in 2023, then advanced by 28.35% to -$9.3 million in 2024, then climbed by 2.44% to -$9.0 million in 2025, then tumbled by 35.81% to -$12.3 million in 2026.
• The last three EBITDA figures came in at -$12.3 million (Q1 2026), -$9.0 million (Q4 2025), and -$8.6 million (Q3 2025), per Business Quant data.